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were surveyed. SAS Version 9.1 (SAS Institute Inc. Cary, NC, USA) was used for data 
analysis. RESULTS: Patients with inhibitors showed higher rate (78%) and frequency 
(2.33 times per year) of hospitalization than those without inhibitors (42%, 1.13 times 
respectively). Also the rate of complications was higher (81%) compared with 59% 
for those without inhibitors. However, patients without inhibitors and those with 
inhibitors did not show statistically signiﬁcant results in hospital visits, drug adminis-
tration status, treatment-related tests (excluding blood tests), and adjuvant treatment. 
CONCLUSIONS: Patients with inhibitors are exposed to higher risk of bleeding and 
complications, which results in a more expensive medical utilization. In this regard, 
more active public subsidy program needs to be developed to prevent the generation 
of inhibitors.
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OBJECTIVES: The objective was to measure health states (HS) associated with 
Immune (Idiopathic) Thrombocytopenic Purpura (ITP), as perceived by members of 
the UK general public. METHODS: Six distinct ITP HS were deﬁned based on platelet 
levels, risk of bleeding, and key adverse events/disease complications. Clinical trial 
data on bleeding and ITP-speciﬁc quality of life data were key sources for developing 
HS descriptions. After a pilot survey, sample size calculation was based on combina-
tions of detectable differences in utility scores between HS, power, and standard 
deviation (SD). A total of 359 respondents, who were randomly selected from a        
managed panel that includes 300,000 individuals in the UK, completed the web-based 
Time Trade-Off survey Sampling and tracking quotas on respondent demographic       
characteristics were performed to ensure representativeness. The Wilcoxon signed 
rank test was used to compare each pair of HS. RESULTS: Sample characteristics 
(mean age: 47.9 years, SD: 16.9; 54% female) were comparable to the UK general 
population. ITP HS were valued as signiﬁcantly worse than perfect health. Experienc-
ing episodes of bleeding was a more important driver than low platelet levels in valuing 
a HS to be worse. Substantial disutilities were associated with surviving an intracranial        
haemorrhage. Mean utility scores for the ITP HSs: HS1: Platelets          q50x109/L, no out-
patient bleed: 0.863 (SD:0.15) HS2: Platelets q50x109/L, outpatient bleed: 0.734 
(SD:0.19) HS3: Platelets 50x109/L, no outpatient bleed: 0.841 (SD:0.19) HS4: Plate-
lets 50x109/L, outpatient bleed: 0.732 (SD:0.19) HS5: Intracranial haemorrhage (2–6 
months): 0.038 (SD:0.46) HS6: Steroid treatment adverse events: 0.758 (SD:0.20) 
CONCLUSIONS: This survey provided evidence that members of the UK general 
population associate a substantial loss of value living in ITP HS. These ﬁndings suggest 
an important role for new ITP treatments and utility scores gained from this survey 
can be used in future cost-effectiveness studies.
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OBJECTIVES: Von Willebrand disease (VWD) is a bleeding disorder affecting about 
1% of the general population. This study explored relationships between bleeding 
disorders, menorrhagia, iron deﬁciency and HRQL. It was hypothesized that females 
with bleeding disorders would have low HRQL associated with menorrhagia and iron 
deﬁciency. METHODS: All males and females with VWD, and females with other 
bleeding disorders, in the Canadian national registry, who were older than 12 years 
of age and literate in English or French, were eligible for survey in this cross-sectional 
population-based study. Measures included the Health Utilities Index Mark 3 utility 
scores of HRQL; abridged Clinical History Assessment Tool for menorrhagia; socio-
demographic questions; and blood for serum ferritin. Iron deﬁciency was deﬁned as 
serum ferritin a20 mcg/L. Statistical analyses included testing differences among 
groups of means using analysis of variance, and of proportions using chi-square. Sta-
tistical signiﬁcance was set at the 5% level. RESULTS: 413 subjects participated. There 
was a signiﬁcant difference (p  0.026) among mean HRQL scores for females with 
VWD (0.701), females with other bleeding disorders (0.783) and males with VWD 
(0.767). Among menstruating females (n  185), there was: no signiﬁcant difference 
(p  0.108) in mean HRQL scores between females with VWD and females with other 
bleeding disorders; a high (p  0.001) prevalence of menorrhagia (44%) compared to 
controls (11%); a signiﬁcant difference (p  0.001) in mean HRQL scores for those 
with / without (0.643 / 0.816) menorrhagia; and no association (p  0.740) between 
menorrhagia and iron deﬁciency. CONCLUSIONS: Females with VWD have lower 
HRQL than females with other bleeding disorders and males with VWD. Menorrhagia 
is prevalent and associated with lower HRQL, but not iron deﬁciency, among men-
struating females with bleeding disorders. Future research should investigate better 
management of menorrhagia for improving HRQL.
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OBJECTIVES: To develop the functions of mapping the 24-item Roland Morris Dis-
ability Questionnaire (RMDQ) for back pain into the EQ-5D and SF-6D utility index. 
METHODS: Data were obtained from the UK BEAM trial, a multi-centre randomised 
trial of physical treatments for back pain in primary care. A total of 1334 patients 
were recruited and completed a battery of questionnaires, including RMDQ, EQ-5D 
and SF-36v2 at the baseline, 1, 3 and 12-month follow-ups. The responses of SF-36v2 
were converted into SF-6D using the published algorithm. Data were divided into two 
groups: one to estimate the mapping functions through regression methods and the 
other to validate the mapping functions. Both overall dataset and sub-datasets of each 
follow-up were examined separately RESULTS: Ordinary least square (OLS) regres-
sion with summary score of RMDQ as independent variable explained 27, 39, 46 and 
53% of variance of observed EQ-5D scores for each follow-up, respectively. Based on 
the overall dataset, OLS regression explained 40 and 44 % of variance with the 
summary score and 18 items of RMDQ as independent variables, respectively. 
However, the mean absolute difference (MAD) of all above models was greater than 
0.13. Meanwhile, models for mapping RMDQ into SF-6D explained only 1 to 4% of 
variance amongst all examined models and datasets. CONCLUSIONS: Based on the 
current ﬁndings, the score of RMDQ for back pain cannot be mapped into the SF-6D 
utility score. The possible cause could be the lack of over-lapping domains between 
two measures. The mapping of RMDQ into EQ-5D could be feasible but applied at 
the group level only. The correlation between RMDQ and EQ-5D increased when 
patients’ pain condition improved. Consequently, the choice of input dataset, overall 
or subset, has a great impact on estimating functions. The ﬁnial selected dataset for 
mapping needs to be justiﬁed.
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Haemophilia is a congenital bleeding disorder with a prevalence of 1:10,000 inhabit-
ants. Treatment of patients with haemophilia requires a substantial amount of eco-
nomical and human resources, why patient-rated outcomes (PROs) such as Quality 
of Life (QoL) and treatment satisfaction (TS) are considered increasingly more impor-
tant in this ﬁeld. For the adequate assessment of PROs cross-culturally validated 
disease-speciﬁc instruments are necessary. OBJECTIVES: Linguistic validation of 3 
haemophilia-speciﬁc PROs for the assessment of TS (Hemo-Sat) and QoL, both in 
children (Haemo-QoL: 3 age group versions for children 4–7, 8–12, 13–16 years and 
their parents) and in adults (Haem-A-QoL) in up to 32 languages. METHODS: For 
languages where no translation existed, the process was conducted by a specialist in 
each target country using the following standardized methodology: (1) two forward 
translations by professional translators, native speakers of the target language and 
ﬂuent in English; (2) comparison and reconciliation of the translations by the specialist 
in the target country; (3) backward translation by a native English speaker; (4) com-
parison of source and backward version; (5) review by the developer for a selection 
of languages; creation of the different forms of the instrument; (6) review by a clini-
cian. RESULTS: The Haemo-QoL was linguistically validated into 32 languages, 
Haem-A-QoL (n  29) and Hemo-Sat (n  19). Besides the challenge of ensuring con-
ceptual equivalence with the original and cultural appropriateness, the translation 
process revealed 2 additional difﬁculties. When translating an expression, appropriate 
terms had to be found for each age group whilst maintaining consistency across all 
versions of the same language. CONCLUSIONS: The language versions of Haemo-
QoL, Haem-A-QoL and Hemo-Sat were established according to a rigorous transla-
tion methodology aiming to ensure conceptual equivalence across different language 
versions facilitating international comparison and pooling of data. The linguistic vali-
dation process is necessary before using PROs in international trials.
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OBJECTIVES: Severe Crohn’s disease management includes anti-Tumour Necrosis 
Factor (anti-TNF) drugs. These drugs differ from the treatments used in early stages 
of the disease in terms of efﬁcacy, safety and convenience. This can modify the impact 
of the disease and its treatment on patients’ lives. The objective of the study was 
to develop a questionnaire assessing patients’ satisfaction with anti-TNF treatments 
in Crohn’s disease. METHODS: A literature review, 3 clinician interviews and 3 
interviews with nurses were carried out as a preparation step. Semi-directive patient 
